Clinical trial
UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026)
NCT00093028 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026)
- Lead sponsor
- University of Arkansas
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- January 31, 2006
- Enrollment
- 315 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.